knowledge -WSS

knowledge

author：comprehensive 2025-09-29 16:32:46 - browse：98849

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： AstraZeneca chief proposes a novel edit to the drug pricing bill

focus

WSS

BMI, flaws aside, is found to be useful estimate of body fat in youth

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

How to increase colonoscopy rates? Looks like an AI can help

Ultragenyx gene therapy for rare liver ailment succeeds in late

Advances in CAR

At ASCO, AstraZeneca reports strong data for breast cancer drug

focus

knowledge

focus

Heart attack and stroke risk calculators need revising

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Moonlake's readout produced a cash windfall. Risks remain

What American doctors can learn from their Israeli counterparts

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

ALS advocates say criticism of new drugs misses bigger picture

Jerome Adams on the need for new antivirals for Covid

Why Novartis is changing the name of its research labs

Wildfire smoke exposes gaps in outdoor worker protections

A rare thyroid diagnosis led to unexpected, all

explore

How to increase colonoscopy rates? Looks like an AI can help

See how much Covid

'Make People Better': The CRISPR babies story you probably don't know

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Humana sues Biden admin over Medicare Advantage audit rule

Cord blood banking comes at a high cost to babies

knowledge

focus

focus

hotspot